Oncolytics Biotech (Oncolytics Biotech) Total Assets : $28.94 Mil (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech Total Assets?

Oncolytics Biotech's Total Assets for the quarter that ended in Dec. 2023 was $28.94 Mil.

During the past 12 months, Oncolytics Biotech's average Total Assets Growth Rate was -24.80% per year. During the past 3 years, the average Total Assets Growth Rate was 7.70% per year. During the past 5 years, the average Total Assets Growth Rate was 19.60% per year. During the past 10 years, the average Total Assets Growth Rate was 20.20% per year.

During the past 13 years, Oncolytics Biotech's highest 3-Year average Total Assets Growth Rate was 105.50%. The lowest was -50.60%. And the median was 1.05%.

Total Assets is connected with ROA %. Oncolytics Biotech's annualized ROA % for the quarter that ended in Dec. 2023 was -37.39%. Total Assets is also linked to Revenue through Asset Turnover. Oncolytics Biotech's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Oncolytics Biotech Total Assets Historical Data

The historical data trend for Oncolytics Biotech's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Total Assets Chart

Oncolytics Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

14.93

26.81

35.84

27.48

28.94

Oncolytics Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial															27.48	25.82	24.06	34.06	28.94

Oncolytics Biotech Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Oncolytics Biotech's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	20.545	+	8.391
	=	28.94

Oncolytics Biotech's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	20.545	+	8.391
	=	28.94

Oncolytics Biotech (NAS:ONCY) Total Assets Explanation

Total Assets is connected with ROA %.

Oncolytics Biotech's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-11.776	/	( (34.062	+	28.936)	/ 2 )
	=	-11.776	/	31.499
	=	-37.39 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Oncolytics Biotech's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0	/	( (34.062	+	28.936)	/ 2 )
=	0	/	31.499
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Oncolytics Biotech Total Assets Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncolytics Biotech (Oncolytics Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

ONC:Canada

Address

322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5

Website

https://www.oncolyticsbiotech.com

Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.